

| | |
|--|----------------------|
| Name – patient ID <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> - <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> - <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px; margin-right: 5px;"></div> <div style="border: 1px solid black; width: 20px; height: 20px;"></div> </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> Day Month year No. </div> | Hospital, department |
|--|----------------------|

Instructions: This form should be completed before inclusion in the protocol. Only if all the boxes of the selected column is ticked, the patient is suitable for treatment according to the protocol. The form is available on DBCG's website (www.dbcg.dk). Choose the Web entry menu, enter Username and Password, follow the instructions as described.

Inclusion criteria:

| | | | | |
|---|--------------------------|-----|--------------------------|----|
| Histologically proven invasive breast carcinoma pT1-3, pN0-N3, M0 or operated after primary systemic therapy for inv. breast carcinoma ypT0-3, ypN0-3, M0 | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Candidate for regional nodes RT without nodal boost | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Woman aged ≥ 18 years | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| WHO performance 0-2 | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Randomisation within 42 days after last surgery or within 4 weeks after last chemotherapy | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Capable of completing therapy, planned follow up visits and investigations | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Fertile women: uses contraception if relevant | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Charlsons morbidity form and pathology form are available | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |
| Informed approval to trial (signed patient folder): | <input type="checkbox"/> | yes | <input type="checkbox"/> | no |

| | | | | | |
|----|--|----|--|----|--|
| | | | | | |
| dd | | mm | | yy | |

Exclusion criteria:

| | | | | |
|---|--------------------------|----|--------------------------|-----|
| Bilateral breast carcinoma | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |
| Previous RT to breast / thorax | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |
| Concurrent / previous malignancy which may influence therapy or follow up | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |
| Pregnant or lactating | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |

| | | | | |
|--|--------------------------|--|--------------------------|------------|
| Surgery | <input type="checkbox"/> | Mastectomy | <input type="checkbox"/> | Lumpectomy |
| Systemic therapy | <input type="checkbox"/> | Endocrine or no systemic therapy | | |
| | <input type="checkbox"/> | Chemotherapy (incl. endocrine / trastuzumab) | | |
| Boost | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |
| Connective tissue disease If yes; diagnosis | <input type="checkbox"/> | no | <input type="checkbox"/> | yes |

| | |
|---|---|
| Filled by DBCG Randomization no. | Form filled in by: Name: _____ <div style="text-align: center;">(CAPITAL LETTERS)</div> Sign.: _____ |
| Result of randomization : <input type="checkbox"/> Regime 1 (Radiotherapy 40 Gy / 15 fr) <input type="checkbox"/> Regime 2 (Radiotherapy 50 Gy / 25 fr) | Date |